October 1, 2020 -- Johnson & Johnson has successfully completed its acquisition of Momenta Pharmaceuticals in an all-cash transaction for approximately $6.5 billion.
The acquisition was completed on October 1. Shares of Momenta were purchased by Johnson & Johnson's tender offer for $52.50 per share. As a result, Momenta's common stock will be delisted from the Nasdaq Global Select Market.
The acquisition will strengthen Johnson & Johnson's presence in the rare disease medicines space.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
